Pharma & Biotech Global Week in Review 23 March 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation (KEI)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.


New IP resource for Pharma, Biotech and Chem – Compulsory licences, comparing national requirements (IP Think Tank)

WIPO and India partner to protect traditional knowledge from misappropriation (WIPO)

UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation (KEI)

Patents and doctors, and the USTR TPP text (KEI)

Biotech industry losing interest in the therapeutic potential of RNAi (Patent Docs)

India: The curious case of the ‘data exclusivity’ volte face (Spicy IP)

Israel: A Purim post – Pharmaceutical company, police beat drug thieves (America-Israel Patent Law)

US: Patent reexamination & expired patents – APP Pharmaceuticals, LLC v. Ameridose  (Patents Post Grant Blog)

US: Sen. Casey takes over the reins for the Creating Hope Act; New bill substantially mirrors Sen. Brownback’s 2010 version (FDA Law Blog)

US: Effective March 28, 2011 – New safety reporting requirements for certain drug and biological products (FDA Law Blog)

US: FDA issues new guidance on PDUFA user fee waivers, reductions, and refunds; guidance represents the culmination of 18 years of FDA experience (FDA Law Blog)

US: Affymetrix files for correction of inventorship: Affymetrix v Illumina (Patent Docs)

US: Hoffman-La Roche files for review and correction of patent term adjustment calculation for patent entitled ‘Anti-Amyloid β Antibodies’ (Patent Docs)

US: Bayh-ing for blood?: Board of Trustees of Leland Stanford Junior University v Roche Molecular Systems Inc (IPKat)

US: That was unexpectedly…  well… expected: BPAI affirms Examiner’s obviousness rejection in Ex Parte Akio Ochiai concerning a health food product containing curcumin, scymnol and isoflavones (BT-IP Notes)

US: VirginiaTech VERSUS series – Drug evaluation DVDs available (FDA Law Blog)


Diovan HCT (Valsartan, Hydrochlorothiazide) – Germany: Düsseldorf District Court issues two decisions in preliminary proceedings in Novartis v Actavis (The SPC Blog)

Diovan HCT (Valsartan, Hydrochlorothiazide) – Norway: Norwegian Valsartan ruling now in English too (The SPC Blog)

Fentora (Fentanyl) – US: Generic’s bioequivalence with brand name drug does not establish infringement of patent protecting brand name drug: Cephalon v Watson (Docket Report)

Gemzar (Gemcitabine) – US: ITC institutes investigation regarding Gemcitabine based on complaint by Eli Lilly against Jiangsu Hansoh Pharmaceutical Co, Intas Pharmaceuticals, ChemWerth and Hospira (ITC 337 Law Blog)

Humira (Adalimumab) – US: You can’t CIP your way out of the written description requirement: Centocor v Abbott (Patent Baristas)

Lidoderm (Lidocaine) – US: Endo files for declaration that Mylan’s Para IV notice is without legal effect and for patent infringement (Patent Docs)

Makena (Hydroxyprogesterone caproate) – US: Note on use of Orphan Drug Act to increase price of hydroxyprogesterone caproate from $10 to $1,500 per dose (KEI)

Nexavar (Sorefenib) – India: Delhi High Court to hear ‘Nexavar’ patent infringement suit tomorrow: Bayer v Cipla (Spicy IP)

Prezista (Darunavir) – US: USA, Illinois University file patent infringement suit against Teva following Para IV certification filing (Patent Docs)

Solaraze (Diclofenac) – US: Glycobiosciences files patent infringement suit against Nycomed, Pharmaderm and Jagotec over manufacture and sale of Solaraze (Patent Docs)

Suprep (Sodium, Potassium, Magnesium) – US: Braintree files patent infringement complaint against Amrutham in response to Para IV challenge (Patent Docs)

Tamiflu (Oseltamivir) – US: Gilead files patent infringement complaints against Natco in New Jersey and Delaware in response to Para IV certification filing (Patent Docs) (IPBiz)

Trilipix (Fenofibrate) – US:  Abbott files patent infringement complaint against Sandoz in response to Para IV certification filing (Patent Docs)

%d bloggers like this: